logo-loader

Poolbeg Pharma: Strong and clear POLB 001 trial data

Published: 19:41 09 Mar 2023 AEDT

Poolbeg Pharma has disclosed selected data from its human volunteer LPS challenge trial (EudraCT N0: 2022-001458-48) with its lead molecule POLB 001, following its initial announcement of the study's success in January. POLB 001 is a small molecule immunomodulator which inhibits p38 MAP Kinase, a well-characterised intracellular signalling molecule associated with the inflammatory response. This pharmaceutical class is known from multiple prior clinical studies to cause reductions in the production of inflammatory cytokines by immune system cells. The POLB 001 data are from a volunteer LPS-challenge study (run in the Netherlands) and clearly show an effect with two dose levels of 70mg and 150mg with rapid responses following administration. Poolbeg also has access to full Phase 1 trial data conducted as part of an earlier development programme by a prior licensee. Together, these data should provide a comprehensive licensing package that will allow a future licensor to take the compound directly into efficacy studies in patients.

Poolbeg states that POLB 001 could be developed further for the treatment of severe influenza and holds use IP covering p38 MAP Kinase inhibitors (including a recently granted US patent) that confers potent protection until at least 2038. Based on WHO data, Poolbeg estimates there may be 3-5mln severe influenza cases a year globally. The main commercial protection will be regulatory (about 10 -12 years, depending on country/region) as POLB 001 could be the first p38 MAP Kinase inhibitor to gain approval. However, the exact indication pursued would be the decision of any future partner.

Although Poolbeg probably has sufficient cash to fund a Phase 2 study, its strategy is to seek an early, probably global partnering deal. A further indication envisaged could be in managing the cytokine release syndrome side effect of CAR T-cell therapies; a current niche, high-value oncology market served by approved products like the anti-IL-6 antibody tocilizumab.

The challenge study tested POLB 001 in 36 healthy volunteers at three dose levels. After repeat dosing over several days, volunteers were challenged with LPS (lipopolysaccharide), a bacterial molecule that triggers an immune response with rapid and diverse cytokine production. Cytokines are potent inflammatory mediator proteins made by immune cells and cause temperature rises, muscle aches and increased heart rates: 'flu symptoms.

POLB 001 showed that at the higher doses (over 70mg) it limited or removed cytokine responses by targeting p38 in immune cells. This worked for both localised and systemic LPS challenges. The oral drug was rapidly absorbed and widely distributed in vivo. Poolbeg did not report any safety issues although longer-term use side effects are known in this class from other studies although this would not be relevant for acute settings such as severe influenza.

What's in the report?

Financial results and forecasts
Growth drivers
Management
Market conditions
Milestones & inflection points
NO INVESTMENT ADVICE

Proactive Investors Australia Pty Ltd ACN 132 787 654 (the Company, we or us) provides you with access to the content set out above, including any news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) and this website (the Site) on the terms set out in this disclaimer, together with all other terms and conditions, disclaimers and other notices displayed elsewhere on this Site.

It is important for you to know that:

(a) none of the Content is, or is intended to be, general or personal advice

(b) the principal purpose of the Content is to provide factual information only and to comment on news;

(c) the Content does not contain or imply any recommendation or opinion intended to influence your financial decisions, including in respect of any particular security, portfolio of securities, transaction or investment strategy, and must not be relied upon by you as such;

(d) in providing you with the Content, we have not considered your objectives, financial situation or needs; and

(e) you should make your own enquiries and obtain your own independent advice prior to making any financial decisions.

The Content contains data (including but not limited to prices, statistics and calculated information) obtained from a variety of third party sources (Third Party Data). The Company does not make any representation or warranty that any of the Content, including the Third Party Data, will be reliable, accurate or complete. The Company disclaims all responsibility and liability arising in any way from any errors or omissions in the Content, including the Third Party Data, including any loss you may incur in connection with any action or decision made by you in reliance upon the Content or Third Party Data.

In certain circumstances the Company, its related bodies corporate, or their affiliates, may have received, or be entitled to receive, financial or other consideration in connection with providing information about certain entities on the Site, which may include the above Content.

FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:

This document is published by Proactive Research and its contents have not been approved as a financial promotion by Proactive Investors Limited or any other FCA authorised person. This communication is made on the basis of the 'journalist exemption' provide for in Article 20 of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and having regard to the FCA rules, and in particular PERG 8.12.

Where the note contains a ‘buy, sell, hold’ recommend, Proactive Investors Limited is authorised to provide investment advice as defined by Article 53 of the RAO

FOR OUR FULL DISCLAIMER CLICK HERE

Poolbeg Pharma Plc: Further expansion of AI-based R&D

Proactive research analyst Robin Davidson joined Proactive's Katie Pilbeam to discuss his latest research note on Poolbeg Pharma PLC (AIM:POLB). Davidson said in his note that Poolbeg's deal with the Israeli artificial intelligence (AI)-based biotech CytoReason to conduct a drug discovery...

on 28/3/22